VistaGen Therapeutics Overview
- Founded
-
1998
- Status
-
Public
- Employees
-
34
- Stock Symbol
-
VTGN
- Investments
-
3
- Share Price
-
$0.27
- (As of Thursday Closing)
VistaGen Therapeutics General Information
Description
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 343 Allerton Avenue
- South San Francisco, CA 94080
- United States
+1 (650) 000-0000
VistaGen Therapeutics Timeline
VistaGen Therapeutics Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.27 | $0.25 | $0.08 - $1.79 | $51.3M | 207M | 6.53M | -$0.32 |
VistaGen Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 | FY 2020 31-Mar-2020 |
|---|---|---|---|---|
| EV | (16,545) | 175,536 | 205,791 | 24,772 |
| Revenue | (186) | 1,109 | 1,090 | 0 |
| EBITDA | (63,784) | (47,068) | (17,456) | (20,698) |
| Net Income | (64,483) | (47,762) | (17,934) | (20,774) |
| Total Assets | 40,702 | 74,643 | 108,281 | 5,772 |
| Total Debt | 3,566 | 3,039 | 3,719 | 4,092 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
VistaGen Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
VistaGen Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and co
Biotechnology
South San Francisco, CA
34
As of 2022
000.00
000000000
000.00
000000
scing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. U
0000 000000000
Coral Gables, FL
00
As of 0000
000.00
000000000
000.00
000000
lor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla paria
0000 000000000
Evanston, IL
00
As of 0000
00000
00000000
00000
Add Comparison
VistaGen Therapeutics Competitors (8)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Relmada Therapeutics | Formerly Angel backed | Coral Gables, FL | 00 | 000.00 | 000000000 | 000.00 |
| 0000000 | Formerly VC-backed | Evanston, IL | 00 | 00000 | 00000000 | 00000 |
| 0000000000000 0000 | Formerly VC-backed | New York, NY | 000 | 00000 | 000000000 | 00000 |
| 0000 000000000000 | Formerly VC-backed | Cambridge, MA | 000 | 00.000 | 000000000 | 00.000 |
| 0000000000 0000000 | Formerly VC-backed | San Diego, CA | 0000 | 00000 | 00000000 | 00000 |
VistaGen Therapeutics Patents
VistaGen Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3178758-A1 | Treatment of adjustment disorders | Pending | 18-May-2020 | ||
| AU-2021277216-A1 | Treatment of adjustment disorders | Pending | 18-May-2020 | 0000000000 | |
| AU-2020271853-A1 | Genetic variants associated with response to treatment of neurological disorders | Pending | 09-Apr-2019 | 0000000000 | |
| CA-3136418-A1 | Genetic variants associated with response to treatment of neurological disorders | Pending | 09-Apr-2019 | 0000000000 | |
| EP-3952856-A4 | Genetic variants associated with response to treatment of neurological disorders | Pending | 09-Apr-2019 | A61K31/198 | 0 |
VistaGen Therapeutics Executive Team (10)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Shawn Singh JD | Chief Executive Officer & Board Member | ||
| Jerrold Dotson | Chief Financial Officer, Finance & Chief Accounting Officer, Accounting | ||
| Reid Adler JD | Chief Legal Officer, Legal | ||
| Caren Scannell | Director, Corporate Development and Communications | ||
| Ann Cunningham | Board Member & Executive |
VistaGen Therapeutics Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000 0000000000 | VistaGen Therapeutics | Board Member & Executive | 000 0000 |
| 000 0000 00 | Self | Chairman & Board Member | 000 0000 |
| 000000 00000000000 | VistaGen Therapeutics | Board Of Director | 000 0000 |
| 00000 00000 00 | VistaGen Therapeutics | Chief Executive Officer & Board Member | 000 0000 |
VistaGen Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
VistaGen Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
VistaGen Therapeutics Acquisitions (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 000000 | 21-Dec-2022 | 0000000000 | Drug Discovery | 00000 000 | |
| 000000000 000 | 11-May-2011 | 0000000000 | Distributors/Wholesale | 00000 000 | |
| Artemis Neuroscience | 19-Nov-2003 | Merger/Acquisition | Pharmaceuticals |
VistaGen Therapeutics ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
34.38 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 1,008
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 465
Rank
00.00
Percentile
